A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dose Regimens With Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects With Moderate to Severe Psoriasis
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Centocor
- 09 Feb 2019 Results published in the Drug Safety
- 28 Aug 2012 New trial record
- 28 Aug 2012 New trial record